secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001104659-23-035061
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M
--------------------------------------------------------------

- Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.
- Q4 2022 gross margin 70% vs 68% a year ago; cash $42.0M at Dec 31.
- OviTex revenue +26% YoY; OviTex PRS +92% YoY; new NIVIS and OviTex LPR launches.
- FY2023 revenue guidance $60-65M (45-57% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/tm239776d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer